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Reprogramming of somatic cells into induced pluripotent stem (iPS) cells by defined pluripotency and self-
renewal factors has taken stem cell technology to the forefront of regenerative medicine. However, a number of
challenges remain in the field including efficient protocols and the threat of cancer. Reprogramming of plant
somatic cells to plant embryonic stem cells using a combination of two plant hormones was discovered in 1957
and has been a routine university laboratory practical for over 30 years. The plant hormones responsible for cell
reprogramming to pluripotency, indole-3-acetic acid (IAA) and isopentenyl adenosine (IPA), are present in
human cells, leading to the exciting possibility that plant hormones might reprogram mammalian cells without
genetic factors. We found that plant hormones on their own could not reprogram mammalian cells but increase
the efficiency of the early formation of iPS cells combined with three defined genetic factors during the first 3
weeks of reprogramming by accelerating the cell cycle and regulating pluripotency genes. Moreover, the cy-
tokinin IPA, a known human anticancer agent, reduced the threat of cancer of iPS cell in vitro by regulating key
cancer and stem cell-related genes, most notably c-Myc and Igf-1. In conclusion, the plant hormones, auxin and
cytokinin, are new small chemicals useful for enhancing early reprogramming efficiency of mammalian cells and
reducing the threat of cancer from iPS cells. These findings suggest a novel role for plant hormones in the biology
of mammalian cell plasticity.
Introduction
In 2006 and 2007, it was demonstrated that a combinationof four genetic factors, Oct4, Sox2 and Klf4 and c-Myc, can
reprogram somatic cells to generate induced pluripotent stem
(iPS) cells in mouse and human cells [1–3]. These cells can
differentiate into any cell of the human body, revolutionizing
the concept of personalized regenerative cell replacement
therapy. This discovery has advanced to date whereby only
two factors are needed in some cell types and a battery of
small chemicals can enhance the survival and efficiency of iPS
cells [4,5]. Despite these technological advances, a number of
bottlenecks remain in the field of iPS cells for application to
study or treat human disease such as efficient reprogramming
protocols and the threat of cancer of their differentiated
progeny for cell replacement therapy.
Interestingly, reprogramming of plant somatic cells into
plant embryonic stem cells using two plant hormones, auxin
and cytokinin, was first demonstrated by Skoog and Miller
in 1957 [6]. With these plant hormones, following an ex-
haustive and intensive testing of cell culture conditions in
several species, including the model plant, Arabidopsis, plant
regeneration systems have been developed [7–10]. Auxins
include several classes of compounds, indole-3-acetic acid
(IAA) being the natural auxin found in plants, whereas there
are several classes of cytokinins, including isopentenyl
adenosine (IPA), a natural compound found in plants that is
active in several plant tissues [10]. IPA is known to bind
transfer-RNA to protect against oxidation and assist in pro-
tein production [11–13]. Furthermore, the anticancer prop-
erties of IPA are very well established in many types of
cancer, including leukemia, breast and colon carcinoma,
suggesting that they might also reduce the tumorigenicity of
iPS cells [14–16].
Both auxins and cytokinins have been found to be present
in human cells suggesting that reprogramming plant cells
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can be recapitulated in mammalian cells [11]. Plant and hu-
man auxin have identical hydrocarbon structures, suggesting
potentially conserved roles for these molecules between
plants and animals. Given the recent interest in reprogram-
ming fibroblasts to iPS cells and the potential for the appli-
cation of these cells in regenerative medicine, we sought to
investigate if we could reprogram fibroblasts with plant
hormones. We show that plant hormones alone cannot re-
program fibroblasts but can increase efficiency of repro-
gramming with three or four defined genetic factors (Oct4,
Sox2, Klf4, c-Myc). Moreover, we found that they specifically
act during the first weeks of reprogramming and effectively
reduce the threat of cancer from iPS cells. We show for the
first time the effect of plant hormones on global gene ex-
pression levels of mammalian cells. Interestingly, we dem-
onstrate that oncogenes such as c-Myc are downregulated,
pluripotency genes such as Oct4 and Rex1 are upregulated
and most notably the aging gene IGF-1 is a target of plant
hormones in mammalian cells.
Methods and Materials
Generation of early iPS cells
The generation of iPS cells using mouse embryonic fibro-
blasts (MEFs) from C57BL/6 mice has been previously
described [17]. MEFs were engineered to express an Oct4-
promoter-driven GFP tag (Oct4-GFP MEFs) and used at
passage 1 to 3 for the reprogramming experiments. Briefly,
for reprogramming experiments, 50,000 or 100,000 cells were
seeded per well of a six-well plate and infected with retro-
viral supernatants of FLAG-tagged pBabe Oct4, Sox2, Klf4,
and/or c-Myc. Infection consisted of a 45-min spinfection at
750 g, washed with phosphate-buffered saline (PBS), and
keratinocyte medium replaced. Two rounds of infections on
consecutive days were performed. Two days after beginning
the last round of infection, cells were trypsinized and seeded
onto feeder layers of irradiated MEFs in the same culture
medium. The medium was changed upon platting to G4
with LIF. The medium was supplemented with a ratio of
1:5 mM of auxin:cytokinin or methanol alone as a control,
following established protocols for reprogramming plant
cells from the first day on feeder layers. Cultures were
maintained at 37C, 5% CO2, with media changes every
other day.
Culture of established mouse iPS cells
with or without plant hormone
The use of previously characterized and established
mouse iPS cells using MEFs from C57BL/6 mice has been
previously described [17]. Mouse iPS cells were maintained
in G4 media, which was changed every day. The final media
formulation included: DMEM (Gibco), 10% fetal bovine se-
rum (FBS, Hyclone), MEM nonessential amino acids (Gibco),
penicillin/streptomycin (10mg/mL each, Gibco), GlutaMAX
(200mM, Gibco), sodium pyruvate (Gibco), 2-mercap-
toethanol (50mM, Gibco), mouse leukemia inhibitory factor
(LIF, 1,000U/mL, Chemicon). We used plant hormones
auxin (IAA) and cytokinin (IPA) following a defined Uni-
versity of Barcelona student protocol for reprogramming
plant cells and also referred to the method described by the
group of Meyerowitz [9]. A ratio of 1:5 mM of auxin:cytokinin
or methanol alone as a control was used following estab-
lished protocols for reprogramming plant cells.
Constructs and virus production
cDNAs for Oct4 and Sox2 were amplified from mouse
embryonic stem cell RNA by RT-PCR. Klf4 was amplified
from IMAGE clone 5111134. c-Myc T58A mutant cDNA was
amplified from DNA kindly provided by Dr. Luciano Di-
Croce. The amplified cDNAs were cloned into the EcoRI/ClaI
sites of a modified pMSCVpuro vector, which allows the
expression of N-terminal FLAG-tagged proteins. Retro-
viruses for the four factors were independently produced
after transfecting the cell line Phoenix Amphotropic using
Fugene 6 reagent (Roche) according to the manufacturer’s
directions. After 24 h, the DMEMmedium was replaced, cells
were incubated at 32C, and the viral supernatant was har-
vested after 24 and 48 h.
Immunofluoresence and AP analysis
Cells were grown on plastic coverslide chambers and fixed
with 4% paraformaldehyde. Secondary antibodies used were
all the Alexa Fluor Series from Invitrogen (all 1:500) as de-
scribed in the figures. Images were taken using a Leica SP5
confocal microscope. Direct alkaline phosphatase activity
was analyzed using an Alkaline Phosphatase Blue/Red
Membrane Substrate solution kit according to the manufac-
turer’s guidelines (Sigma).
In vitro differentiation
Differentiation toward endoderm, mesoderm, and neu-
roectoderm was carried out by plating embryoid bodies
(EBs) on gelatin and DMEM medium with 20% FCS changed
every second day for 2–3 weeks. Differentiation toward
neurons was performed by adding EBs to matrigel thin-
coated plates and kept in neural basal medium (50% neural
basal medium, 50% F12 medium) with N2/B27 growth
supplement and 1 mM retinoic acid for 3 week. Cells were
then stained for appropriate markers described in the figures.
Flow cytometry analyses
All analyses were performed on a MoFlo cell sorter (Dako
Cytomation) running Summit software. For measuring pro-
liferation, we have used the commercial kit from Invitrogen
the Click-iT EdU AlexaFluor647 Flow Cytometry Assay kit
following the manufacturer’s instructions (LifeTEch). For the
proliferation assay using the click-IT kit, instead of using the
supplied DNA dyes, we used a home-made DNA DAPI
staining solution (0.1M Tris Base pH 7.4; 0.9% or 150mM
NaCl; 1mM CaCl2; 0.5mM MgCl2; 0.2% BSA; 0.1% Nonidet
P40; 10mg/mL DAPI) and 0.5mL/test (2 h at RT or overnight
4C). Details of the procedure have been published [18].
Microarray
Microarray was performed at the Val d Hebron Research
Institute microarray platform. Mouse Agilent 4· 44K, two
colors, gene expression arrays were used. Data were ana-
lyzed by the same platform and presented either as global
gene expression differences or as gene sets based on cell
function in the respective figures.
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Real-time PCR
Total mRNA was isolated using TRIZOL and 1mg was
used to synthesize cDNA using the Invitrogen Cloned AMV
First-Strand cDNA synthesis kit. 1–2 mL of the reaction was
used to quantify gene expression by qPCR for transgenes
and endogenous pluripotent genes as previously described.
Soft agar assay
Briefly, six-well plates were coated with 1mL of 0.4%
Agar/G4 medium gel, between 25,000 and 2,500 mESC,
mouse leukemia cells or iPS cells plated in a 0.3% gel placed
on top. LIF (1,000 Units/mL) was maintained in all condi-
tions, but low serum (1% FCS) and high serum (15% FCS)
was used in the agar gels to control growth factor conditions.
0.5mL of G4 media was changed every 3 days at 37C, 5%
CO2, and after 2–3 weeks, stained with 1% commassie blue
for 10min, washed with PBS once and the number of colo-
nies counted. The media and soft agar gel contained 5mM of
cytokinin or methanol alone, as a control throughout the
experiment.
Results
Plant hormones increase efficiency of mammalian
cell reprogramming to iPS cells
We first sought to test if plant hormones could reprogram
mammalian cells on their own. To do this, we first examined
if the plant hormone auxin and a panel of plant hormone
cytokinin forms (including ZR, zeatin riboside; Z, zeatin;
DHZ, dihydrozeatin; K, kinetin; 2-IP, isopentenyl; IPA, iso-
pentenyl adenine) could regulate pluripotency gene expres-
sion. We chose the auxin IAA (Fig. 1A) because it is the
preferred auxin for plant cell reprogramming while we tes-
ted a battery of cytokinins all known for plant cell repro-
gramming (Fig. 1B). For plant cell reprogramming, a 5:1 ratio
of IAA:IPA was used. We found that after a series of ex-
periments for mammalian cells the reverse ratio of 1:5
IAA:IPA had the best effect on mammalian pluripotency
gene expression (Supplementary Fig. S1 and S2; Supple-
mentary Data are available online at www.liebertpub.com/
scd). Most notably, we observed that a ratio of 5mM IPA to
1 mM IAA, upregulated Oct3/4, Utf1, and Rex1 gene expres-
sion (Fig. 1B).
Given we had shown that plant hormones could regulate
pluripotency genes, we next tested if the ratio of 1mM auxin
IAA:5 mM cytokinin IPA could reprogram MEFs by their
own or in combination with three or four standard repro-
gramming factors Oct4, Sox2, Klf4, and c-Myc. We found that
plant hormones cannot reprogram MEFs on their own nor
could they reprogram MEFs in combination with one factor
(Oct4) or with two factors (Oct4/Sox2) (Fig. 1C). As a control
for this experiement, we observed with three factors or four
factors iPS cell colonies at 2–3 weeks, as expected.
We next asked the question if plant hormones could in-
crease the efficiency of reprogramming with defined factors.
We engineered a MEF cell line with an Oct4-promoter-driven
GFP reporter gene (Oct4-GFP MEFs) and reprogrammed
these cells either three factors (Oct4, Sox2, Klf4) or four factors
(plus c-Myc) with and without 1mM auxin IAA:5 mM cyto-
kinin IPA treatment. We demonstrate that in the presence of
plant hormones an increase in the number of colonies and
intensity of GFP signal during the early (3 to 4 weeks) stage
of reprogramming by colony formation assay (Fig. 1D). We
show by microarray gene expression analysis that plant
hormones can increase the expression of the key plur-
ipotency genes Oct4 and Nanog during the early repro-
gramming period (Fig. 1D). To quantify the colony formation
assay, we used flow cytometry to measure the number of
GFP-positive cells during reprogramming of Oct4-GFP-MEF
cells with and without plant hormone treatment. In the
presence of IAA and IPA, Oct4-GFP-MEF demonstrated a
twofold increase in the number of GFP-positive cells after 3
weeks of reprogramming with Oct4/Sox2/Klf4/c-Myc (Fig.
1E). Taken together, we demonstrate that 1mM auxin:IAA
5 mM cytokinin IPA plant hormone treatment of MEFs can
increase the efficiency of reprogramming twofold by regu-
lating the expression of key pluripotency genes.
Plant hormones auxin and cytokinin regulate cell
cycle of mammalian cells during reprogramming
We next sought to understand the mechanism by which
plant hormones auxin IAA and IPA can increase the effi-
ciency of reprogramming. It is well established that IPA
regulates the cell cycle of plant cells and that IAA regulates
plant cell senescence. Therefore, we analyzed the effect of
IPA and IAA on the cell cycle of the MEFs by flow cytometry
using EdU staining. We found that plant hormones can in-
crease the S-phase stage of the cell cycle by approximately
double with a concurrent reduction of cells in the G1-phase
of the cell cycle (Fig. 2A). We found that there is little to no
effect on apoptosis of MEFs during the early reprogramming
stage (Fig. 2A).
To determine if plant hormones affected the pluripotency
of iPS cells over long term, we characterized iPS cells after
long-term treatment (longer than 4 weeks) and demonstrated
no detectable differences in pluripotency marker expression
for Nanog and SSEA1 (Fig. 2B). Moreover, we did not detect
an effect on the S-phase with plant hormone treatment of
established iPS cells, suggesting that plant hormones only act
during the early reprogramming stages (Fig. 2B).
To understand in more detail the mechanism, we per-
formed a microarray analysis of the effect of plant hormones
on mouse cell cycle and apoptosis genes with and without
treatment with plant hormones. We found that there are a
number of cell cycle-related genes expression upregulated by
plant hormones (Fig. 2C). Moreover, we show by real-time
PCR analysis that pluripotency genes FGF4, Oct4, Sox2, and
UTF1 gene expression are upregulated with plant hormone
treatment in early reprogramming cells (Fig. 2D). Interest-
ingly, we show that plant hormone treatment reduced the
expression of the oncogene c-Myc during reprogramming
(Fig. 2D). Taken together, we show that the mechanism of
action of plant hormones to increase efficiency of repro-
gramming of mammalian cells is by accelerating the cell
cycle and increasing pluripotency gene expression levels,
without significantly affecting apoptosis levels, and this ef-
fect does not affect established iPS cells (Fig. 2B).
Cytokinin IPA reduces tumorigenicity of iPS cells
Given our observation that plant hormone treatment
reduced c-Myc expression (Fig. 2D) and that IPA is a
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well-established anticancer agent in many different cancer
types, we next asked if plant hormone treatment could re-
duce the tumorigenicity of iPS cells their differentiated
progeny in vitro. We confirmed previous published data that
plant hormone IPA can kill mouse leukemia cancer cells by
slowing the cell cycle and increasing apoptosis (Fig. 3A).
Next, we differentiated iPS cells under general conditions
(DMEM plus 20% FBS) and guided conditions toward neu-
ronal stem cells (retinoic acid plus N2/B27 in F12/DMEM)
and tested the ability of IPA to reduce the threat of cancer.
We used an in vitro soft agar approach to test a major hall-
mark of malignant cancer, namely, anchorage-independent
and growth factor-deprived colony formation. We show
from repetitive experiments a reduced colony formation in
both iPS cells and fibroblast-like cells from general differen-
tiation conditions are significantly reduced with the treat-
ment of plant hormone IPA (5mM) (Fig. 3B). Importantly, we
show that plant hormone can reduce the ability of differen-
tiated fibroblast-like cells to undetectable levels in a soft agar
assay (Fig. 3B). In addition, using directed differentiation
toward neuronal stem cells over 4 weeks in a soft agar assay
iPA treatment reduced colony formation in soft agar (Fig. 3C,
D). Histological analysis by immunofluorescence demon-
strated the neural stem cells were positive for TUJ1 and
MAP2 markers (Fig. 3C). Soft agar assay of the neural stem
cells with and without plant hormone cytokinin IPA signif-
icantly reduced the ability of these cells to grow in anchor-
age-independent and growth factor-deprived conditions
(Fig. 3D). Taken together, the data demonstrate plant hor-
mone IPA treatment of iPS cells and differentiated progeny.
The differentiated stem cells would in theory be the cell state
used for cell replacement therapy and plant hormone IPA
can significantly reduce the threat of cancer to low or un-
detectable levels.
FIG. 1. (A) Schematic diagram of the chemical structure of plant hormone auxin, indole-3-acetic acid (IAA), and cytokinin,
isopentenyl adenosine (IPA). (B) Graph of RT-PCR of pluripotent gene expression levels in primary mouse embryonic
fibroblasts (MEFs) treated with auxin and a panel of cytokinins as described for 24 h. The first cytokinin, ZR used high auxin/
low ZR and the second ZR on the graph used low auxin/high ZR ratio. The experiment was performed in triplicate and
independently twice. ZR, zeatin riboside; Z, zeatin; DHZ, dihydrozeatin; K, kinetin; 2-IP, isopentenyl; IPA, isopentenyl
adenine. (C) Colony formation assay of developing induced pluripotent stem (iPS) cells made from Oct4-GFP MEFs treated
with or without plant hormone auxin and cytokinin IPA (5mM). Colonies are stained at 3 weeks of development with alkaline
phosphatase. The colony formation assay was performed independently three times. (D) Phase-contrast and GFP fluores-
cence microscopy photos of early reprogramming iPS cell colonies derived from Oct4-GFP MEFs at the 3 week stage treated
with and without plant hormone auxin and cytokinin IPA. Note an increase in iPS colony numbers and GFP-positive colonies
with plant hormone treatment. The experiment was performed independently three times. · 100. Right panel shows heat map
from microarray analysis of pluripotency gene expression. A: Auxin IAA; IPA: Cytokinin. (E) Flow cytometry graphs of the
number of Oct4-GFP-positive cells at the 3-week stage of reprogramming with or without plant hormone auxin and cytokinin
IPA treatment (5mM). Color images available online at www.liebertpub.com/scd
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Cytokinin downregulates mammalian IGF-1
gene expression
To investigate further how IPA plant hormone treatment
is reducing the ability of iPS cells to form cancer, we per-
formed a microarray gene expression analysis. We found
from all cancer-related gene expression (mouse leukemia cell
line) that IPA regulates the expression of 432 mammalian
cancer-related genes in iPS cells and 69 cancer-related genes
in mouse cancer (leukemia) cells (Fig. 4A). Only three genes
were found to be regulated by IPA in both iPS cells and
cancer cells (Fig. 4A). To validate the microarray experiment,
we analyzed four genes that are of high interest to the field of
cancer research, Cdh1, Igf-1, Hox d11, and Hox d13 by real-
time PCR gene expression analysis. We found that the Hox
genes were not validated in iPS cells; however, Cdh1 mouse
gene expression is upregulated threefold by plant hormone
and Igf-1 gene expression is downregulated fourfold (Fig.
4C). Taken together, the data demonstrate that plant hor-
mone IPA treatment acts on key cancer-related genes c-Myc,
Cdh1, and Igf-1 gene expression. These data suggest that
plant hormone IPA reduces the threat of cancer of iPSC via
these signaling pathways, most notably the suppression of c-
Myc (Fig. 2D) and Igf-1 gene expression (Fig. 4C). This
mechanism may be specific to iPS cells because we did not
detect any change in a mouse leukemia cell line in Cdh1, Fgf4,
FIG. 2. (A) Flow cytometry graphs of cell cycle profile of early reprogramming iPS cell colonies derived from MEFs at 3
weeks stage measured by EdU (upper panels) with and without plant hormone auxin and cytokinin IPA (5mM). Lower panels
show flow cytometry graphs of apoptosis levels of early reprogramming iPS cell colonies derived from MEFs at 3 weeks stage
measured by DilC with and without plant hormone auxin and cytokinin IPA (5 mM). The experiment was performed
independently three times. (B) Upper panels: Characterization of pluripotency of iPS cell clones after 4 weeks treated with and
without plant hormone. Confocal microscope photos of immunoflorescence staining for pluripotency markers; Nanog
and SSEA1 for established iPS cell clones treated long term with plant hormone. This experiment was repeated three times
and representative photos shown. Lower panels show flow cytometry graphs of cell cycle profile of established iPS cell clone
measured by EdU (upper panels) with and without plant hormone auxin and cytokinin IPA (5mM). Note no change in S-phase
with plant hormone treatment. (C) Gene expression microarray heat maps of cell cycle genes and apoptosis genes of early
reprogramming iPS cell colonies derived from MEFs at the 3 weeks stage with and without plant hormone auxin and
cytokinin IPA (5 mM). (D) Graph of real-time RT-PCR gene expression levels of pluripotency genes of early reprogramming
iPS cell colonies derived from Oct4-GFP MEFs at the 3-week stage treated with and without plant hormone auxin and
cytokinin IPA (5mM). The experiment was performed in duplicate and a representative experiment shown. Color images
available online at www.liebertpub.com/scd
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Hox d11, Hox d13, or Igf-1 gene expression levels with plant
hormone IPA treatment (Fig. 4C).
Discussion
Plant cells, unlike animal cells, have the ability to regen-
erate themselves in response to injury using specific combi-
nations of plant hormones. In 1957, it was discovered that
plant hormones could reprogram plant somatic cells to plant
embryonic stem cells that can recapitulate the development
of an entire plant (Skoog, 1957 #65). Here, we have investi-
gated if plant hormones auxin and cytokinin IPA can re-
program mammalian cells to pluripotency. Our findings
demonstrate that IAA:IPA treatment alone is insufficient to
reprogram mammalian cells to pluripotency. However,
when combined with traditional three- and four-factor re-
programming protocols, plant hormone treatment increased
the efficiency of reprogramming by accelerating the cell cycle
and increasing pluripotent gene expression levels. Addition
of plant hormone to established iPS cell clones did not alter
the cell cycle nor pluripotency markers SSEA1 and Nanog,
suggesting that the effect of the plant hormones affect the
reprogramming process (Fig. 2B). Further work to charac-
terize iPS cells made with plant hormone treatment is war-
ranted; however, our data suggest that the quality of the iPS
cells will be increased in the presence of IAA:IPA, given that
they regulate key pluripotency genes during reprogram-
ming. Furthermore, we demonstrate that the cytokinin IPA
reduces oncogenic transformation of iPS cells and their dif-
ferentiated progeny to very low levels in vitro.
These findings have a number of far reaching implications
in the field of reprogramming and in regenerative medicine.
First, the use of plant hormones could become a routine
small chemical to increase efficiency of making iPS cells,
similar to HDAC and MEK inhibitors. Second, character-
ization of the mechanism by which plant hormone treatment
FIG. 3. (A) Flow cytometry histograms of mouse leukemia cells treated with plant hormone cytokinin iPA (5mM) and cell
cycle measured by Edu stating or apoptosis by DilC method performed. Note that plant hormone cytokinin IPA increases
apoptosis and reduces cell cycle in mouse leukemia cells. (B) Graph of soft agar assay colony numbers of iPS cells and
mesenchymal stem cell-like fibroblasts differentiated for 2 weeks under general differentiation conditions, treated with
and without plant hormone cytokinin IPA (5mM). Photo of representative colonies growing in soft agar of iPSC treated with and
without plant hormone auxin and cytokinin IPA (5mM). · 100. (C) Photos of mouse iPS cell were differentiated to neurons over
4 weeks with neural basal medium plus retinoic acid and N2/B27 supplements and stained for TUJ1 and MAP2 expression
(· 200 magnification). (D) Graph of soft agar assay colony numbers of differentiated neural stem cells differentiated for 4 weeks
treated with and without plant hormone cytokinin IPA (5mM). Photos of representative colonies growing in soft agar of cells
treated with and without plant hormone auxin and cytokinin IPA (5mM). Note that cytokinin IPA reduces the ability of neural
stem cells to form anchorage-independent growth. · 200. Color images available online at www.liebertpub.com/scd
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can regulate mammalian pluripotency genes could reveal
new targets for reprogramming. Third, the use of cytokinin
IPA would be an ideal naturally occurring small chemical
compound for routine use to reduce the threat of cancer
posed by iPS cell-derived cells for cell replacement therapy.
Although it remains to be tested if IPA treatment of iPS cells
and differentiated progeny can reduce cancer in vivo, this
work has established the first observation that IPA, a well-
known anticancer agent [14–16], can reduce oncogenic
transformation of iPS cells.
This study is the first of its kind to explore the effect of plant
hormones auxin and cytokinin on mammalian cell gene ex-
pression levels. The data reveal interesting gene targets of plant
hormones on mammalian genes, such as c-Myc, Cdh1, Fgf4,
and Igf-1, all involved in cancer and stem cell biology. Cyto-
kinin IPA suppression of oncogenic transformation in iPS cells
most likely acts through its suppression of c-Myc gene ex-
pression (Fig. 1) and regulation of Cdh1 and Igf-1 and gene
expression. Cdh1 encodes the E-cadherin protein and is upre-
gulated by plant hormones in developing iPS cells. Loss of E-
cadherin function or expression has been implicated in cancer
progression and metastasis suggesting that plant hormones
reduce the threat of cancer of iPS by upregulating E-cadherin.
Cdh1 is emerging as a key regulator of human and mouse stem
cell pluripotency and self-renewal; however, it remains to be
seen if loss-of-function and gain-of-function studies can con-
firm this finding. Insulin-like growth factor (IGF) signaling
mediates many critical cell responses, including mitogenesis,
proliferation, growth, differentiation, and angiogenesis, and is
downregulated by plant hormones during reprogramming of
mammalian cells (Fig. 4C). The IGF signaling pathway has a
pathogenic role in cancer, and recent studies have shown that
increased levels of IGF lead to increased growth of existing
cancer cells [19]. The regulation of these genes by plant hor-
mones strongly suggests that IAA and IPA have important
roles in both the regulation of the pluripotent state as well as
the cellular defenses against oncogenesis.
In conclusion, given that the chemical structure of plant
and human auxin is identical and that cytokinin IPA is found
in human cells bound to tRNA assisting protein expression,
presumably supplied by the consumption of vegetables in
the diet, and that we observe a positive effect of plant hor-
mones on pluripotency and key anticancer gene expression
levels in mammalian cells, it is likely that plant hormones
could offer a method for increasing the safety of iPS cells for
therapeutic applications. While loss and gain of function
studies as well as in vivo studies are needed to further define
the mechanism of plant hormone action on Igf-1, c-Myc, and
Cdh1 genes during iPS reprogramming, this study demon-
strates a novel use of plant hormones for increasing the ef-
ficiency and safety of iPS cells for cell replacement therapy
and regenerative medicine in the near future.
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